Saturday, March 28, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Mr. Ron Chapman II, a top legal mind in healthcare compliance and opioid litigation

Mr. Ron Chapman II began his career as an officer in the U.S. Marine Corps and was deployed to combat in Afghanistan. He achieved the rank of Captain before transitioning to law.

He graduated from Loyola School of Law, where he received his Master of Laws (LL.M.) with a concentration in health care compliance.

He quickly established himself as a premier healthcare defense counsel, and is among the few attorneys to have achieved trial acquittals on behalf of clients charged with healthcare financial fraud or improper opioid prescribing.

He now shares his wisdom and learned experiences in the book – Fight the Feds: Unraveling Federal Criminal Investigations. To purchase his book, please select the link below:

To learn more about Mr. Chapman’s legal work and his firm, Chapman Law Group, please select the link below:

https://www.chapmanlawgroup.com/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!